Summary
Chlorothiazide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Obesity would be drug repurposing rather than first-in-human development. This does not mean it is approved for Obesity. ClinicalTrials.gov lists 8 registered trials linking Chlorothiazide to Obesity: 1 is currently recruiting; 6 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00239538). It plans or enrolled 840 participants. Registration activity spans 2003 to 2016. No published literature item is linked to Chlorothiazide and Obesity in the OSMF database yet, so the record rests on registry entries alone. Registry entries describe intent to study, not outcomes.
The RepurpOS disease-intelligence file for Obesity ranks 368 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: Sustained weight loss of >5% without intervention: ~5-10% at 2 years; weight regain almost universal after behavioural intervention alone (95% return to within 5% of starting weight at 5 years on lifestyle alone).
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 49.0 (trials 29.0, literature 0.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 1 recruiting, 0 active / not yet recruiting, 6 completed, 1 other |
| Linked publications | 0 |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | DGIdb |
| Linked via biomarker / target | CA4 |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT00775814 | Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension. 2006 | completed | Phase 4 | 188 |
| NCT00239538 | SMOOTH - Blood Pressure Control in Diabetic/Obese Patients 2003 | completed | Phase 4 | 840 |
| NCT01138423 | Treatment of Adiposity Related hypErTension (TARGET) 2010 | completed | Phase 4 | 32 |
| NCT00459056 | The Vascular Effects of Carvedilol Controlled Release (CR) in Abdominally Obese Hypertensive Patients 2007 | completed | Phase 3 | 25 |
| NCT00282178 | Double-Blind Randomized Cross-Over Trial Comparing Metabolic Effects of Candesartan, Hydrochlorothiazide and Placebo 2005 | completed | Phase 2 | 26 |
| NCT01983462 | Vascular Dysfunction in Human Obesity Hypertension 2013 | terminated | Phase 2 | 33 |
| NCT00871871 | Multiple Dose Effects of Hydrochlorothiazide and Isosorbide Mononitrate on Glucose Homeostasis (MK-0000-117)(Completed) 2009 | completed | Phase 1 | 64 |
| NCT03476551 | Bariatric Surgery and Pharmacokinetics of Hydrochlorothiazide 2016 | recruiting | Not applicable | 12 |
Published literature
No publication is linked to this pair yet.
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CA4. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Chlorothiazide approved for Obesity?
Chlorothiazide has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Obesity would be drug repurposing rather than first-in-human development. This does not mean it is approved for Obesity. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Chlorothiazide in clinical trials for Obesity?
ClinicalTrials.gov lists 8 registered trials linking Chlorothiazide to Obesity: 1 is currently recruiting; 6 have completed; 1 is terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT00239538). It plans or enrolled 840 participants. Registration activity spans 2003 to 2016.
What does the evidence show for Chlorothiazide in Obesity?
Chlorothiazide has 6 completed registered trials for Obesity but no linked publication, which usually means results are unpublished, pending, or not yet matched to this record. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in DGIdb, in this case via the biomarker or target CA4. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.